It is not just about willpower
Today, GLP-1 medications derived from this biological blueprint have become among the most prescribed weight loss therapies worldwide
The single most significant near-term opportunity is the genericization wave anticipated between 2026 and 2030, during which time the progressive expiry of Novo Nordisk's semaglutide patent portfolio across major markets will enable dozens of generic pharmaceutical companies to enter the semaglutide formulation market, each requiring third-party API supply
Our medical team reviews your health history before starting treatment
10.1016/j.freeradbiomed.2018.06.037 38 LeiG.ZhuangL.GanB
[DOI] [PMC free article] [PubMed] [Google Scholar] 32.Kong F., Wu T., Dai J., Zhai Z., Cai J., Zhu Z., et al